US Edition
Published • loading... • Updated
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm alleges Ultragenyx misled investors about its drug's efficacy, with the Phase III trial failing to reduce fracture rates significantly, causing investor losses.
Summary by WFMZ
10 Articles
10 Articles
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a)…
·Pennsylvania, United States
Read Full Article
Watauga Democrat+6 Reposted by 6 other sources
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, March 29, 2026 /PRNewswire/ -
·Calhoun, United States
Read Full Article
Mt. Airy NewsReposted by 
The Free Press
The Free PressKD Investors Have Opportunity to Lead Kyndryl Holdings, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
NEW YORK, March 29, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Kyndryl Holdings, Inc. (NYSE: KD) between August 7, 2024 and February 9, 2026, both dates inclusive (the "Class…
Coverage Details
Total News Sources10
Leaning Left2Leaning Right1Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 29%
C 57%
14%
Factuality
To view factuality data please Upgrade to Premium
